Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach

5Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Commonly used non-antibiotic drugs have been associated with changes in gut microbiome composition, paving the way for the possibility of repurposing FDA-approved molecules as next-generation microbiome therapeutics. Herein, we developed and validated an ex vivo high-throughput screening platform─the mini gut model─to underpin human gut microbiome response to molecular modulators. Ten FDA-approved compounds, selected based on maximum structural diversity of molecular fingerprints, were screened against the gut microbiome of five healthy subjects to characterize the ability of human-targeted drugs to modulate the human gut microbiome network. Three compounds, THIP hydrochloride, methenamine, and mesna, have shown promise as novel gut microbiome therapeutics in light of their capability of promoting health-associated features of the gut microbiome. Our findings provide a resource for future research on drug-microbiome interactions and lay the foundation for a new era of more precise gut microbiome modulation through drug repurposing, aimed at targeting specific dysbiotic events.

Cite

CITATION STYLE

APA

Barone, M., Rampelli, S., Biagi, E., Bertozzi, S. M., Falchi, F., Cavalli, A., … Candela, M. (2021). Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. Journal of Medicinal Chemistry, 64(23), 17277–17286. https://doi.org/10.1021/acs.jmedchem.1c01333

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free